A Nijmegen-based public-private partnership received 1.5 million Euro from the European Fund for Regional Development (EFRO).With this grant, the consortium aims to develop novel therapeutics against mosquito-transmitted tropical infectious diseases, such as Malaria, dengue virus and Zika virus.
The consortium consists of the spinoff companies Protinhi Therapeutics, TropIQ Health Sciences, both based at the Novio Tech Campus, and scientists from Radboud University (dr. Martin Feiters, prof. Floris Rutjes) and Radboud University Medical Center (dr. Ronald van Rij, prof. Robert Sauerwein).
More information (in Dutch): read more.
Related news items
A personal touch of Kartika Hapsari18 September 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Kartika Hapsari.read more
Radboud study on Dirty Money wins Ig Nobel Prize17 September 2019
By shaking hands we are exchanging bacteria. Does this happen without direct hand-to-hand contact, for example when paying with paper money? Andreas Voss, clinical microbiologist at Radboudumc and CWZ, and colleagues in the United States received an Ig Nobel Prize for research into dirty money.read more
MMD Lecturer of the year award for Alessandra Cambi16 September 2019
At their annual MMD symposium, Alessandra Cambi, theme Nanomedicine, was chosen as lecturer of the year 2018-2019 of the Top Master "Molecular Mechanisms of disease".read more
Artificial intelligence for renal tissue assessment16 September 2019
Meyke Hermsen and Jeroen van der Laak, present an alternative approach, featuring a convolutional neural network for multi-class segmentation of periodic acid–Schiff-stained kidney tissue sections. Their work was published in the Journal of the American Society of Nephrology.read more